17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Ahnak functions as a tumor suppressor via modulation of TGFβ/Smad signaling pathway

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We provide detailed mechanisms of Ahnak-mediated potentiation of transforming growth factor β (TGFβ) signaling, which leads to a negative regulation of cell growth. We show that Smad3 interacts with Ahnak through MH2 domain and that Ahnak stimulates Smad3 localization into nucleus leading to potentiating TGFβ-induced transcriptional activity of R-Smad. Moreover, overexpression of Ahnak resulted in growth retardation and cell cycle arrest through downregulation of c-Myc and cyclin D1/D2. We describe results from analyses of Ahnak −/− mouse model expressing middle T antigen in a mammary gland-specific manner (MMTV Tg/+Ahnak −/−), which showed significantly progressed hyperplasia of mammary glands compared with MMTV Tg/+Ahnak +/+. Finally, we screened multiple human breast cancer tissues and showed that the expression of Ahnak in cancer tissues is lower than that in control tissues by 50%. Taken together, these data indicate that Ahnak mediates a negative regulation of cell growth and acts as novel tumor suppressor through potentiation of TGFβ signaling.

          Related collections

          Most cited references28

          • Record: found
          • Abstract: found
          • Article: not found

          Identification of c-MYC as a target of the APC pathway.

          The adenomatous polyposis coli gene (APC) is a tumor suppressor gene that is inactivated in most colorectal cancers. Mutations of APC cause aberrant accumulation of beta-catenin, which then binds T cell factor-4 (Tcf-4), causing increased transcriptional activation of unknown genes. Here, the c-MYC oncogene is identified as a target gene in this signaling pathway. Expression of c-MYC was shown to be repressed by wild-type APC and activated by beta-catenin, and these effects were mediated through Tcf-4 binding sites in the c-MYC promoter. These results provide a molecular framework for understanding the previously enigmatic overexpression of c-MYC in colorectal cancers.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Principles of tumor suppression.

            Molecular genetic studies of familial cancer syndromes identified and defined the recessive nature of tumor suppressor genes and resolved the paradox of why tumors arising in such families exhibited an autosomally dominant pattern of inheritance. Subsequent characterization of tumor suppressor proteins revealed their widespread involvement in sporadic cancers and pinpointed key mechanisms that protect animals against tumor development. We now recognize that tumor suppressor genes regulate diverse cellular activities, including cell cycle checkpoint responses, detection and repair of DNA damage, protein ubiquitination and degradation, mitogenic signaling, cell specification, differentiation and migration, and tumor angiogenesis. Their study has become a centerpiece of contemporary cancer research.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment?

              Cell division relies on the activation of cyclins, which bind to cyclin-dependent kinases (CDKs) to induce cell-cycle progression towards S phase and later to initiate mitosis. Since uncontrolled cyclin-dependent kinase activity is often the cause of human cancer, their function is tightly regulated by cell-cycle inhibitors such as the p21 and p27 Cip/Kip proteins. Following anti-mitogenic signals or DNA damage, p21 and p27 bind to cyclin-CDK complexes to inhibit their catalytic activity and induce cell-cycle arrest. Interestingly, recent discoveries suggest that p21 and p27 might have new activities that are unrelated to their function as CDK inhibitors. The identification of new targets of Cip/Kip proteins as well as evidence of Cip/Kip cytoplasmic relocalization have revealed unexpected functions for these proteins in the control of CDK activation, in the regulation of apoptosis and in transcriptional activation. This article discusses recent insights into these possible additional functions of p21 and p27.
                Bookmark

                Author and article information

                Journal
                Oncogene
                Oncogene
                Oncogene
                Nature Publishing Group
                0950-9232
                1476-5594
                18 September 2014
                24 March 2014
                : 33
                : 38
                : 4675-4684
                Affiliations
                [1 ]Department of Life Sciences and GT5 program, Ewha Womans University , Seoul, Korea
                [2 ]Laboratory of Developmental Biology and Genomics, College of Veterinary Medicine, Seoul National University , Seoul, Korea
                [3 ]College of Pharmacy, Gachon University , Incheon, Korea
                [4 ]Department of Surgery, School of Medicine, Seoul National University , Seoul, Korea
                [5 ]Department of Obstetrics and Gynecology, Samsung Hospital, SungKyunKwan University , Seoul, Korea
                Author notes
                [* ]Laboratory of Developmental Biology and Genomics, College of Veterinary Medicine, Seoul National University, Daehak-dong , Seoul 151-742, Korea E-mail: snumouse@ 123456snu.ac.kr
                [* ]Department of Life Sciences and GT5 program, Ewha Womans University, Daehyun-Dong , Seoul 120-750, Korea. E-mail: baeys@ 123456ewha.ac.kr
                [6]

                These authors contributed equally to this work.

                Article
                onc201469
                10.1038/onc.2014.69
                4180639
                24662814
                43c7aba8-8659-4112-8eba-4de16e7ba12b
                Copyright © 2014 Macmillan Publishers Limited

                This work is licensed under a Creative Commons Attribution 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0/

                History
                : 18 June 2013
                : 15 December 2013
                : 24 December 2013
                Categories
                Original Article

                Oncology & Radiotherapy
                Oncology & Radiotherapy

                Comments

                Comment on this article